Universität zu Köln

Kreissl, Stefanie, Goergen, Helen, Mueller, Horst, Meissner, Julia, Mehnert, Anja, Buerkle, Carolin, Fuchs, Michael, Engert, Andreas, Behringer, Karolin and Borchmann, Peter (2019). Survivors' perspectives on risks and benefits of Hodgkin lymphoma treatment: results of a survey by the German Hodgkin Study Group. Leuk. Lymphoma, 60 (6). S. 1389 - 1399. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Full text not available from this repository.

Abstract

We performed a survey in Hodgkin lymphoma survivors to learn more about their perspectives on treatment risks and benefits. We sent questions to 1149 survivors from the GHSG's HD13-15 trials with (N=249) or without (N=900) documented progression or relapse. The participation rate was 52% (N=581). After median follow-up of 106 months, 40% of relapse-free and over 60% of relapsed survivors were still worried about late effects and the possibility of relapse. Chemotherapy, largely independent of its intensity, had been a strain on 74% of relapse-free and 90% of relapsed survivors. Most physical, psychological, and socio-economic sequelae were more frequent among relapsed survivors (p<.05) and described as very burdensome. 74% of relapse-free and 61% of relapsed survivors considered primary cure from Hodgkin lymphoma as the most important aspect in the choice of treatment. Accordingly, primary optimal lymphoma control is of utmost importance from the patients' perspective.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Kreissl, Stefanie UNSPECIFIED UNSPECIFIED UNSPECIFIED Goergen, Helen UNSPECIFIED UNSPECIFIED UNSPECIFIED Mueller, Horst UNSPECIFIED UNSPECIFIED UNSPECIFIED Meissner, Julia UNSPECIFIED UNSPECIFIED UNSPECIFIED Mehnert, Anja UNSPECIFIED UNSPECIFIED UNSPECIFIED Buerkle, Carolin UNSPECIFIED UNSPECIFIED UNSPECIFIED Fuchs, Michael UNSPECIFIED UNSPECIFIED UNSPECIFIED Engert, Andreas UNSPECIFIED UNSPECIFIED UNSPECIFIED Behringer, Karolin UNSPECIFIED UNSPECIFIED UNSPECIFIED Borchmann, Peter UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-148311
DOI:	10.1080/10428194.2018.1540781
Journal or Publication Title:	Leuk. Lymphoma
Volume:	60
Number:	6
Page Range:	S. 1389 - 1399
Date:	2019
Publisher:	TAYLOR & FRANCIS LTD
Place of Publication:	ABINGDON
ISSN:	1029-2403
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language STEM-CELL TRANSPLANTATION; CANCER-RELATED FATIGUE; DOSE-INTENSIFICATION; ADAPTED TREATMENT; OPEN-LABEL; STAGE-III; 8 CYCLES; ABVD; CHEMOTHERAPY; INTENSITY Multiple languages Oncology; Hematology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/14831